CorMedix (CRMD)
(Delayed Data from NSDQ)
$4.06 USD
-0.16 (-3.79%)
Updated Aug 5, 2024 04:00 PM ET
After-Market: $4.06 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth C Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CRMD 4.06 -0.16(-3.79%)
Will CRMD be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CRMD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CRMD
Does CorMedix (CRMD) Have the Potential to Rally 135.51% as Wall Street Analysts Expect?
Wall Street Analysts Predict a 146.21% Upside in CorMedix (CRMD): Here's What You Should Know
CRMD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why CorMedix (CRMD) Looks Ripe for Bottom Fishing
How Much Upside is Left in CorMedix (CRMD)? Wall Street Analysts Think 198.21%
Cidara Therapeutics (CDTX) Reports Q4 Loss, Misses Revenue Estimates
Other News for CRMD
Commit To Purchase CorMedix At $3, Earn 39.7% Annualized Using Options
Biotech Alert: Searches spiking for these stocks today
Biotech Alert: Searches spiking for these stocks today
These 2 “Strong Buy” Penny Stocks Are Poised for a Big Rally, Say Analysts
CorMedix price target lowered by $2 at Truist, here's why